Clinical trials
Diabetes (Insulin-requiring, Type 1 or Type 2) clinical trials
Below are recruiting diabetes (insulin-requiring, type 1 or type 2) clinical trials, each written for real people, not researchers. We’re tracking 2,152 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06169579Enrolling by invitationPhase 1
Trial of ND-003 for advanced solid cancers
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Xiamen, FujianAges 18 years+ - NCT06176690RecruitingPhase 1
Donor cell therapy for CD30-positive lymphomas
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
Houston, TexasAges 12–75 - NCT05512208RecruitingPhase 2
Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Orlando, FloridaAges 18–99 - NCT06091254RecruitingPhase 3
Comparing odronextamab to standard chemo for untreated follicular lymphoma
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
Tucson, ArizonaAges 18 years+ - NCT06100237RecruitingPhase 2
Teclistamab and daratumumab for high-risk smoldering myeloma
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
Miami, FloridaAges 18 years+ - NCT06087029Recruiting
Improving outcomes in aortic dissection
This study tests a minimally invasive procedure called TEVAR to repair a type B aortic dissection (a tear in the wall of the main artery from your heart). It may help prevent further damage and improve recovery.
Birmingham, AlabamaAges 21 years+ - NCT06086873Recruiting
Comparing two dental implant surfaces for healing
This study compares two types of dental implant surfaces to see which helps the implant bond better with the jawbone after a tooth is pulled. It may help you if you need a single front tooth or first premolar replaced.
LondonAges 18 years+ - NCT04260022RecruitingPhase 1
Drug study for hard-to-treat CML or Ph+ ALL
This Phase 1 study tests HQP1351 for people with CML or Ph+ ALL that has not responded well to standard targeted pills (TKIs), or those who could not tolerate them. It’s designed to see whether the treatment can work and how safe it is for this difficult-to-treat group.
Birmingham, AlabamaAges 18 years+ - NCT06075771RecruitingPhase 4
Testing a Parkinson's drug for depression-related loss of interest
This trial tests whether a medication used for Parkinson's disease (carbidopa-levodopa) can help people with major depression who have lost interest or pleasure in things. It is for adults who have not been helped enough by other treatments and have signs of inflammation.
Atlanta, GeorgiaAges 25–55 - NCT06044935Recruiting
Nicotinamide riboside for fat burning and metabolism
This study tests whether a supplement called nicotinamide riboside (a form of vitamin B3) helps the body burn fat more efficiently during exercise. It may be a good option if you are overweight or have a specific type of diabetes (MODY2) and want to see if a natural supplement can boost your metabolism.
Bethesda, MarylandAges 18–65 - NCT06034405Recruiting
Checking spine tissue for heart amyloidosis signs
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
Beverly Hills, CaliforniaAges 50 years+ - NCT06025747RecruitingPhase 1
Abemaciclib plus radiation for liposarcoma before surgery
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
Seattle, WashingtonAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Gilbert, ArizonaAges 18 years+ - NCT05959356RecruitingPhase 2
First-line treatment for left-sided metastatic colon cancer with specific tumor markers
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
Foshan, GuangdongAges 18 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT05973448Enrolling by invitation
Nightlight Falls Prevention for People With Dementia
This study tests a simple plan to help prevent falls in people who have dementia. You may be able to join if you live in a participating assisted living community and meet the safety and room rules.
Chapel Hill, North CarolinaAges 18 years+ - NCT05954429RecruitingPhase 2
Study of fruquintinib plus immunotherapy after standard CRC treatment
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05949125RecruitingPhase 1
Immune cell therapy for advanced acute myeloid leukemia
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
Ulm, Baden-WurttembergAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Los Angeles, CaliforniaAges 18 years+ - NCT05953584RecruitingPhase 2
Etavopivat for preventing stroke risk in sickle cell children
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Raipur, ChhattisgarhAges 12–16 - NCT05933499RecruitingPhase 2
Tirzepatide and bimagrumab for body fat and insulin sensitivity
This Phase 2 study tests two medicines to see how they change body fat, insulin sensitivity, and bone health in adults with obesity. It may help people who have tried lifestyle changes to lose weight but have not been able to, though diabetes and several health conditions must be ruled out first.
Boston, MassachusettsAges 18 years+ - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05880810Recruiting
Home patients with diabetes trial a continuous glucose monitor
This study tests a continuous glucose monitor (a sensor that tracks glucose) for people with type 1 or type 2 diabetes who receive care at home through Mayo’s Advanced Care at Home program. It may help by improving how safely and accurately blood sugar is followed while you’re at home.
Jacksonville, FloridaAges 18 years+
Hear when a new Diabetes (Insulin-requiring, Type 1 or Type 2) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diabetes (insulin-requiring, type 1 or type 2)?
- Yes. Clin2 currently lists 2,152 recruiting diabetes (insulin-requiring, type 1 or type 2) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diabetes (insulin-requiring, type 1 or type 2) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diabetes (insulin-requiring, type 1 or type 2) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.